Relationship between overexpression of the FLT3 transcript and clinical characteristics in 91 AML cases without FLT3/ITD
. | Total, N = 91 . | FLT3 transcripts more than 200 000 copies/μg RNA, N = 5 . | FLT3 transcripts less than or equal to 200 000 copies/μg RNA, N = 86 . |
|---|---|---|---|
| Age, y (range) | 48 (15-85) | 43 (21-69) | 48 (15-85) |
| Older than 60 y, n | 27 | 2 | 25 |
| WBC count, × 109/L (range) | 23.4 (1.2-211) | 56.1 (24.7-197.4) | 22.2 (1.2-211) |
| More than 100 × 109/L, n | 14 | 1 | 13 |
| FAB | |||
| M0 | 2 | 1 | 1 |
| M1 | 19 | 1 | 18 |
| M2 | 45 | 2 | 43 |
| M4 | 18 | 1 | 17 |
| M5 | 6 | 0 | 6 |
| M6 | 1 | 0 | 1 |
| M7 | 0 | 0 | 0 |
| Cytogenetics | |||
| Favorable | 20 | 1 | 19 |
| t(8; 21) | 17 | 1 | 16 |
| inv(16) | 3 | 0 | 3 |
| Intermediate | 67 | 4 | 63 |
| Poor | 4 | 0 | 4 |
| t(9; 22) | 2 | 0 | 2 |
| del(7) | 2 | 0 | 2 |
| Outcome | |||
| CR | 71 | 2 | 69 |
| Failure | 20 | 3 | 17 |
| MLL-TD mutation | 9 | 2 | 7 |
| p53 gene mutation | 2 | 0 | 2 |
| N-RAS gene mutation | 14 | 1 | 13 |
| FLT3/D835 mutation | 5 | 0 | 5 |
. | Total, N = 91 . | FLT3 transcripts more than 200 000 copies/μg RNA, N = 5 . | FLT3 transcripts less than or equal to 200 000 copies/μg RNA, N = 86 . |
|---|---|---|---|
| Age, y (range) | 48 (15-85) | 43 (21-69) | 48 (15-85) |
| Older than 60 y, n | 27 | 2 | 25 |
| WBC count, × 109/L (range) | 23.4 (1.2-211) | 56.1 (24.7-197.4) | 22.2 (1.2-211) |
| More than 100 × 109/L, n | 14 | 1 | 13 |
| FAB | |||
| M0 | 2 | 1 | 1 |
| M1 | 19 | 1 | 18 |
| M2 | 45 | 2 | 43 |
| M4 | 18 | 1 | 17 |
| M5 | 6 | 0 | 6 |
| M6 | 1 | 0 | 1 |
| M7 | 0 | 0 | 0 |
| Cytogenetics | |||
| Favorable | 20 | 1 | 19 |
| t(8; 21) | 17 | 1 | 16 |
| inv(16) | 3 | 0 | 3 |
| Intermediate | 67 | 4 | 63 |
| Poor | 4 | 0 | 4 |
| t(9; 22) | 2 | 0 | 2 |
| del(7) | 2 | 0 | 2 |
| Outcome | |||
| CR | 71 | 2 | 69 |
| Failure | 20 | 3 | 17 |
| MLL-TD mutation | 9 | 2 | 7 |
| p53 gene mutation | 2 | 0 | 2 |
| N-RAS gene mutation | 14 | 1 | 13 |
| FLT3/D835 mutation | 5 | 0 | 5 |
Mean (minimum to maximum) values are indicated for age and WBC count. Number of cases is shown by age (> 60 years), WBC count (> 100 × 109/L), FAB, cytogenetics, outcome, and gene mutations. The favorable risk group was defined by t(8;21) or inv(16), the poor risk group by t(9;22) or del(7), and the intermediate risk group by normal or other karyotypes and karyotype unknown. CR indicates complete remission.